Statistics from Altmetric.com
The evidence-based practice (EBP) model hierarchically organises scientific information by level, from lowly case studies to lofty systematic reviews and clinical trials. Clinical trials best influence recommendations because they putatively have the greatest internal validity.1 This assumption is based on sound research ethics, such as scientific competence and good faith actors, as well as observed differences in outcomes. An EBP blind spot emerges when fundamental assumptions are unmet. Based on findings of a 2018 PEDro evidence summary in BJSM 2 and elsewhere,3 it now seems clear that scientific research in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) resides in a blind spot.
ME/CFS—a multisystem condition
ME/CFS is estimated to affect 836 000 to 2.5 million people in the USA.4 Ninety per cent of cases are thought to go undiagnosed,4 suggesting that people with ME/CFS are substantially undercounted, underdiagnosed and undertreated. Substantial literature exists to support that ME/CFS is a multisystem condition that appears associated with a combination of genetic, cellular and systemic metabolic deficits in …
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent Not required.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.